Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER
- 1 December 1992
- journal article
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 6 (12) , 2167-2174
- https://doi.org/10.1210/me.6.12.2167